| Sathyaprasad C Burjonrappa, MD | |
|
125 Paterson St Ste 3300, New Brunswick, NJ 08901-1962 | |
| (732) 235-7821 | |
| Not Available |
| Full Name | Sathyaprasad C Burjonrappa |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 31 Years |
| Location | 125 Paterson St Ste 3300, New Brunswick, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144322561 | NPI | - | NPPES |
| NE0W8 | Other | FL | BLUE CROSS BLUE SHIELD |
| 100539000 | Medicaid | FL |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rutgers Health-rwj Neurosurgery Faculty | 4587613443 | 95 |
News Archive
In a new Biological Psychiatry article, Dr. Regina Sullivan and colleagues have dissected the behavior of mother rats and their infant pups, modeling nurturing by stroking and abuse with electric shock. In this animal model of infant abuse, they took into consideration the unique infant neurobehavioral learning attachment system that ensures infant rats' attachment to their caregiver regardless of the quality of care received.
A team of investigators at Brown University has developed a novel way to treat a class of breast cancer cells. The team has created twin nanoparticles that specifically targets the Her-2 tumor cell and unload a cancer-fighting drug directly into it. The result is a boost in antitumor activity while minimizing side effects. The findings of this study have been published in the Journal of the American Chemical Society.
Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.
Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today announced Annual 2009 financial results ended June 30, 2009.
A team of scientists from the United States demonstrates that rapid antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more effective in determining the actual infection status in patients with coronavirus disease 2019 (COVID-19) than real-time polymerase chain reaction (RT PCR)-based tests.
› Verified 4 days ago
| Entity Name | Rutgers Health-rwj Neurosurgery Faculty |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083738637 PECOS PAC ID: 4587613443 Enrollment ID: O20050118000611 |
News Archive
In a new Biological Psychiatry article, Dr. Regina Sullivan and colleagues have dissected the behavior of mother rats and their infant pups, modeling nurturing by stroking and abuse with electric shock. In this animal model of infant abuse, they took into consideration the unique infant neurobehavioral learning attachment system that ensures infant rats' attachment to their caregiver regardless of the quality of care received.
A team of investigators at Brown University has developed a novel way to treat a class of breast cancer cells. The team has created twin nanoparticles that specifically targets the Her-2 tumor cell and unload a cancer-fighting drug directly into it. The result is a boost in antitumor activity while minimizing side effects. The findings of this study have been published in the Journal of the American Chemical Society.
Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.
Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today announced Annual 2009 financial results ended June 30, 2009.
A team of scientists from the United States demonstrates that rapid antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more effective in determining the actual infection status in patients with coronavirus disease 2019 (COVID-19) than real-time polymerase chain reaction (RT PCR)-based tests.
› Verified 4 days ago
| Entity Name | Rutgers Health-rwj Pediatric Surgery |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487736146 PECOS PAC ID: 0244277853 Enrollment ID: O20050414001115 |
News Archive
In a new Biological Psychiatry article, Dr. Regina Sullivan and colleagues have dissected the behavior of mother rats and their infant pups, modeling nurturing by stroking and abuse with electric shock. In this animal model of infant abuse, they took into consideration the unique infant neurobehavioral learning attachment system that ensures infant rats' attachment to their caregiver regardless of the quality of care received.
A team of investigators at Brown University has developed a novel way to treat a class of breast cancer cells. The team has created twin nanoparticles that specifically targets the Her-2 tumor cell and unload a cancer-fighting drug directly into it. The result is a boost in antitumor activity while minimizing side effects. The findings of this study have been published in the Journal of the American Chemical Society.
Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.
Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today announced Annual 2009 financial results ended June 30, 2009.
A team of scientists from the United States demonstrates that rapid antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more effective in determining the actual infection status in patients with coronavirus disease 2019 (COVID-19) than real-time polymerase chain reaction (RT PCR)-based tests.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sathyaprasad C Burjonrappa, MD Po Box 829642, Philadelphia, PA 19182-9642 Ph: (866) 470-6626 | Sathyaprasad C Burjonrappa, MD 125 Paterson St Ste 3300, New Brunswick, NJ 08901-1962 Ph: (732) 235-7821 |
News Archive
In a new Biological Psychiatry article, Dr. Regina Sullivan and colleagues have dissected the behavior of mother rats and their infant pups, modeling nurturing by stroking and abuse with electric shock. In this animal model of infant abuse, they took into consideration the unique infant neurobehavioral learning attachment system that ensures infant rats' attachment to their caregiver regardless of the quality of care received.
A team of investigators at Brown University has developed a novel way to treat a class of breast cancer cells. The team has created twin nanoparticles that specifically targets the Her-2 tumor cell and unload a cancer-fighting drug directly into it. The result is a boost in antitumor activity while minimizing side effects. The findings of this study have been published in the Journal of the American Chemical Society.
Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.
Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today announced Annual 2009 financial results ended June 30, 2009.
A team of scientists from the United States demonstrates that rapid antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more effective in determining the actual infection status in patients with coronavirus disease 2019 (COVID-19) than real-time polymerase chain reaction (RT PCR)-based tests.
› Verified 4 days ago
Huong Truong, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901 Phone: 480-452-4711 | |
Gustavo Bauza, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 125 Paterson Street Suite 6300, Robert Wood Johnson Medical School Division Of Acs, New Brunswick, NJ 08901 Phone: 732-235-7766 | |
Dr. Marc William Lafonte, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901 Phone: 732-828-3000 | |
Albert Assad, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 254 Easton Ave, New Brunswick, NJ 08901 Phone: 732-745-8571 Fax: 732-249-5284 | |
Dr. Jennifer To, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 125 Paterson St Ste 6300, New Brunswick, NJ 08901 Phone: 732-235-7766 Fax: 732-235-2964 | |
Dr. Georg N Herlitz, MD Surgery Medicare: Medicare Enrolled Practice Location: 125 Paterson St, Clinical Academic Building, Dept Of Surgery, New Brunswick, NJ 08901 Phone: 646-382-2730 | |
Victoria Needham, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 125 Paterson St Ste 4100, New Brunswick, NJ 08901 Phone: 732-235-7920 |